New York, NY, USA, 18 January 2022:
Evotec partner Celmatix Inc., a biotechnology company focused on ovarian biology, today announced that a third milestone has been achieved in its five-year, multi-target alliance with Evotec. The milestone was triggered by Evotec and Bayer AG advancing a drug programme, centered around a novel Celmatix-identified drug target, into hit-identification.
Worldwide, hundreds of millions of women are struggling with PCOS, the most common endocrine disorder in premenopausal women. While the underlying cause of PCOS is largely unknown, genomic studies suggest a strong genetic connection.
For further information, please follow this link to the full version of the press release from Celmatix.